QC
TGTX icon

Quent Capital’s TG Therapeutics TGTX Stock Holding History

Quent Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-138
Closed -$2.08K – 1346
2023
Q1 		$2.08K Buy
138
+110
+393% +$1.67K ﹤0.01% 1162
2022
Q4 		$331 Hold
28
– – ﹤0.01% 1266
2022
Q3 		$0 Hold
28
– – ﹤0.01% 1279
2022
Q2 		$0 Hold
28
– – ﹤0.01% 1306
2022
Q1 		$0 Buy
+28
New +$324 ﹤0.01% 1326

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Quent Capital's TGTX Position: Q2 2023 in Review

Quent Capital sold out of TG Therapeutics (TGTX) in Q2 2023, closing a stake of 138 shares — an estimated $2.08K sold.

Quent Capital first reported a position in TGTX in Q1 2022 and held it in 5 quarters. The position peaked at $2.08K in Q1 2023. 244 funds tracked by Wall St. Rank hold TGTX as of Q2 2023.

  • Quent Capital reported no remaining TG Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Quent Capital sold 138 TG Therapeutics shares in Q2 2023, an estimated $2.08K.
  • Quent Capital first reported a position in TG Therapeutics in Q1 2022 and held it in 5 quarters.
  • Quent Capital's TG Therapeutics position peaked at $2.08K in Q1 2023.
  • 244 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2023.

Based on Quent Capital's 13F filing for Q2 2023, filed 10 Jul 2023.